1.8% of adults globally.

Borderline Personality Disorder (BPD)

Research into psychedelic-assisted therapies for Borderline Personality Disorder (BPD) indicates promising potential, particularly with compounds such as ketamine and MDMA, which may enhance emotional processing and neuroplasticity. However, systematic exclusion of BPD patients from psychedelic trials has limited available data, highlighting the need for dedicated research in this area.

What is Borderline Personality Disorder (BPD)?

Borderline personality disorder (BPD) is a complex mental health condition characterised by profound instability in identity, relationships, and emotional regulation. Individuals with BPD often display impulsive behaviours, intense anger, chronic feelings of emptiness, suicidal ideation, and self-harm.

The pathophysiology of BPD is multifactorial, involving genetic predispositions, neurobiological dysregulation, and significant environmental stressors. Genetic factors may account for around 40% of the disorder's heritability, while neurochemical imbalances—particularly in serotonin systems—contribute to symptoms of mood instability and impulsivity.

Environmental factors such as childhood trauma, emotional neglect, and socioeconomic disadvantage are significant risk variables. BPD frequently co-occurs with other psychiatric conditions, diminishing treatment efficacy and complicating the clinical landscape.

Current Treatments

First-line treatment for BPD typically involves psychotherapy, primarily dialectical behaviour therapy (DBT) and mentalisation-based therapy (MBT). Medications may be prescribed for comorbid conditions but do not consistently improve core BPD features.

Psychedelic Effect Matrix

Systematic comparison of compound efficacy and evidence levels for Borderline Personality Disorder (BPD).

Compound	Magnitude	Evidence	Consistency
Ketamine Emerging studies indicate significant effects on mood and impulsivity; however, data specific to BPD is still sparse.	Large	Moderate	Inconsistent
MDMA Potential benefits inferred from PTSD treatments, but lack of direct research on BPD limits conclusions.	Medium	Low	Inconsistent
Psilocybin Highlights from PTSD research suggest potential, yet BPD-specific data remain undeveloped.	Medium	Low	Inconsistent

Ketamine and Borderline Personality Disorder (BPD)

Ketamine acts as a non-competitive NMDA receptor antagonist, offering rapid antidepressant effects that may significantly benefit individuals with BPD, particularly those experiencing co-occurring depressive symptoms. Its unique mechanism may enhance neuroplasticity, addressing the emotional dysregulation core to BPD by facilitating reparative processes within dysfunctional neural circuits.

View full Ketamine profile →

MDMA and Borderline Personality Disorder (BPD)

MDMA acts primarily on serotonin, dopamine, and norepinephrine systems, fostering emotional openness and reducing fear responses. Its potential utility in BPD stems from its ability to enhance therapeutic engagement during sessions, which may lead to profound emotional insights and improved interpersonal relationships, critical for addressing the instability characteristic of BPD.

View full MDMA profile →

Psilocybin and Borderline Personality Disorder (BPD)

Psilocybin primarily engages the 5-HT2A receptor, influencing emotional processing and cognitive flexibility. This compound holds promise for BPD as it may help individuals re-evaluate their emotional patterns and stabilize their sense of self, alongside promoting introspection during therapeutic experiences.

View full Psilocybin profile →

Key Insights

1
BPD affects up to 2.7% of the population, significantly burdening healthcare systems.
2
Psychedelic therapies including ketamine and MDMA have been proposed to enhance emotional regulation and neural adaptability, crucial for BPD treatment.
3
Most current studies on psychedelics focus on comorbid conditions, rather than BPD itself, highlighting a research gap.
4
MDMA-assisted therapy shows promise for PTSD, which shares symptomatology with BPD, raising interest in its applicability for BPD populations.
5
Emerging studies suggest ketamine's potential benefits for suicidality and depression in individuals with BPD.

Industrial Landscape

Key players in the psychedelic space include Compass Pathways, which is developing psilocybin therapy for treatment-resistant depression, and MindMed, exploring LSD formulations for anxiety. Both companies have focused historically on populations outside of BPD due to safety concerns, with a growing call for more inclusive research practices.

Quick Indicators

Prevalence1.8% of adults globally.

Research Footprint

0Trials

0Papers

\"Ongoing clinical evaluations are investigating Borderline Personality Disorder (BPD) as a primary indication for various psychedelic compounds.\"

Key Organizations

4 Connected

Delix Therapeutics

Delix Therapeutics is harnessing the power of neuroplastogens, a novel class of compounds designed to bring about a new paradigm in brain health therapeutics with treatments intended to be safe, fast-acting, and long-lasting. Through its discovery platform, Delix has identified non-hallucinogenic versions of psychedelic compounds with favorable safety and therapeutic profiles. The company was co-founded in 2019 by David E. Olson and Nick Haft, building upon Olson's discovery at the University of California, Davis, of several novel psychoplastogens that have significant therapeutic potential in preclinical models, without hallucinogenic side effects. Delix's treatments are designed to address the root cause of neuropsychiatric conditions by repairing the underlying synaptic damage through targeted neuroplasticity. To date, the company has synthesized over 2000 novel psychoplastogens, many of which are analogs of known psychedelics such as ibogaine and 5-MeO-DMT. Their lead compound, zalsupindole (DLX-001), produces the same rapid and sustained structural and functional plasticity as ketamine, psilocybin, and DMT, without inducing hallucinations or dissociation. Recent Phase I data have demonstrated that DLX-001 is associated with robust signs of CNS engagement and a favorable safety and tolerability profile, with no serious adverse events reported to date. The company's compounds are tailored for swift neuronal repair and can be taken at-home, providing significant advantages to patients, their loved ones, and healthcare providers. Delix focuses on developing non-hallucinogenic psychoplastogens as scalable alternatives to first-generation hallucinogenic psychoplastogens like ketamine and psilocybin.

MAPS

The description of the stakeholder

Lykos Therapeutics

Longer description of Lykos .. lorem ipsum ..

Leiden University

Leiden University doesn't have a dedicated research centre for psychedelics. However, several staff members from their medical centre and psychology faculty are working with psychedelics. Researchers here are working with other universities including Utrecht University as well as Compass Pathways.